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Abstract
Background: Hepatic fibrosis is characterized by intense tissue remodeling, mainly driven by matrix
metalloproteinases. We previously identified CO3-610, a type III collagen neoepitope generated by matrix
metalloproteinase (MMP)-9, and tested its performance as a fibrosis marker in rats with bile-duct ligation. In this
study, we assessed whether CO3-610 could be used as a surrogate biomarker of liver fibrosis and portal
hypertension in carbon tetrachloride-induced experimental fibrosis.
Results: For this study, 68 Wistar rats were used. Serum CO3-610 was measured by ELISA. Liver fibrosis was
quantified by Sirius red staining. Serum hyaluronic acid (HA) was measured with a binding-protein assay. Gene
expression of collagens I and III, Mmp2 and Mmp9, and tissue inhibitors of matrix metalloproteinase 1 (Timp1) and
2(Timp2) was quantified by PCR. Hemodynamic measurements were taken in a subgroup of animals. A close direct
relationship was found between serum CO3-610 and hepatic collagen content (r = 0.78; P < 0.001), superior to that
found for serum HA (r = 0.49; P < 0.05). CO3-610 levels in rats with severe fibrosis (43.5 ± 3.3 ng/mL, P < 0.001)
and cirrhosis (60.6 ± 4.3 ng/mL, P < 0.001) were significantly higher than those in control animals (26.6 ± 1.3 ng/
mL). Importantly, a highly significant relationship was found between serum CO3-610 and portal hypertension (r =
0.84; P < 0.001). Liver Mmp9 expression increased significantly in fibrotic animals but decreased to control levels in
cirrhotic ones.
Conclusions: Circulating CO3-610 behaves as a reliable indicator of hepatic remodeling and portal hypertension in
experimental fibrosis. This peptide could ultimately be a useful marker for the management of liver disease in
patients.
Background
Identification of non-invasive biochemical markers of
liver fibrosis is a major challenge for scientists and clini-
cians dealing with hepatic diseases. The degree of liver
fibrosis has emerged as the primary determinant in the
diagnosis, prognosis and management of patients with
chronic liver diseases [1,2]. Furthermore, the probably
availability of antifibrotic treatments in the near future 3
emphasizes the necessity of having accurate tools that
allow the sequential evaluation of changes in collagen
turnover induced by these drugs.
Liver biopsy (LB) is the gold standard method for the
diagnosis of liver fibrosis, providing a unique source of
information on fibrosis and assessment of histology.
Even for patients in whom serologic tests point to a spe-
cific liver disease, LB can give valuable additional infor-
mation regarding staging, prognosis and management
[4]. However, LB can be painful and carries a risk, albeit
slight, of complications, some of which may be life-
threatening, and therefore it is often reserved for cases
in which clinical cirrhosis or the diagnosis of the type of
liver disease is unclear. The size and quality of the
biopsy, interpretation of histology, and the heterogeneity
of fibrosis deposition between patients are variables that
can lead to errors and inaccurate assessment of fibrosis
[5]. In the past few years, the list of non-invasive
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sively. Indirect biomarkers, such as platelet count or
liver transaminases, reflect alterations in hepatic func-
tion but not changes in extracellular matrix (ECM)
turnover [6,7]. By contrast, direct biomarkers are
thought to be involved in the deposition or removal of
the ECM. The extensive deposition of fibrous tissue,
together with the active remodeling and recurrent scar-
ring that develops during fibrosis, results in increased
serum levels of the constituents and degradation pro-
ducts of fibrous tissue [7,8]. This group includes col-
lagens, proteoglycans, matrix glycoproteins, HA, matrix
metalloproteinases (MMPs) and their inhibitors (tissue
inhibitors of matrix metalloproteinases; TIMPs), and
several cytokines involved in fibrosis signaling pathways.
The most extensively studiedc o l l a g e n - d e r i v e dm a r k e r s
in liver fibrosis are the N-terminal propeptide of type III
procollagen (PIIINP) and type IV collagen [8-11]. Indir-
ect and direct markers of liver fibrosis have been vali-
dated alone or in combination in different groups of
patients with differing degrees of hepatic dysfunction.
However, wide agreement on the most suitable biomar-
ker of liver fibrosis is far from being reached.
Recently, a new strategy based on the identification of
neoepitopes arising from the cleavage of ECM compo-
nents by matrix proteolytic enzymes has been proposed
[12]. This strategy assumes that collagen cleavage occurs
at significant levels only during the gross alterations in
ECM homeostasis seen during fibrosis. Neoepitopes,
which are cleared into the circulation in peptide frag-
ments, are almost completely absent under healthy con-
ditions, and detectable only when active fibrosis is
ongoing. This, in turn, raises the possibility of discrimi-
nating between different degrees of disease activity.
Based on this approach, we recently identified CO3-610,
a specific peptide fragment of type III collagen gener-
ated by MMP-9, as a potential liver fibrosis biomarker,
and developed an ELISA assay to quantify it in serum
[13]. Initial tests of this assay, particularly its perfor-
mance in rats with bile-duct ligation (BDL) have been
previously reported [14].
In the present study we assessed whether the circulat-
ing levels of CO3-610 could be used as a surrogate mar-
ker of liver fibrosis and portal hypertension in
experimental fibrosis induced by carbon tetrachloride
(CCl4) in rats.
Results
Fibrosis quantification and staging
The liver of animals treated with CCl4 had a finely
granulated surface macroscopically. As anticipated, the
individual response to the fibrosis-induction protocol
varied widely from animal to animal. Hence, based on
histological analysis, CCl4-treated rats were staged into
three groups according to the percentage of fibrotic area
compared with the total area of the LB: mild and mod-
erate fibrosis (defined as the fibrotic area being < 6% of
the total; n = 33), severe fibrosis (6 to 11%; n = 15) and
cirrhosis (> 11%; n = 20). Control rats displayed no
appreciable alterations in liver histology, and had an
almost negligible amount of fibrous tissue. However, in
fibrotic rats, there was progressive accumulation of
ECM as a consequence of the continuous liver injury,
evolving from a slight deposition of fibrosis mainly in
the portal area (mild/moderate fibrosis) to numerous
and thicker septa resulting from the longer exposure to
CCl4 (severe fibrosis). Finally, most of the animals
exposed to the toxin for the longest periods developed
cirrhosis, characterized by the formation of regenerative
nodules of liver parenchyma separated by fibrotic septa.
Figure 1 shows representative Sirius red staining of tis-
sue from a control rat, a rat with mild/moderate fibrosis,
a rat with severe fibrosis and a rat with cirrhosis.
The fibrotic/cirrhotic ratsi n c l u d e di nt h es t u d yh a d
important alterations in liver-function tests, being more
pronounced in the group of rats with cirrhosis (Table
1). These animals also had a moderate but significant
alteration in extracellular fluid homeostasis, as reflected
by hyponatremia.
CO3-610 is a 25 kDa circulating fragment of collagen
type III detected in the serum of cirrhotic rats
Western blotting analysis of serum samples from cirrho-
tic and control rats precipitated with the anti-CO3-610
antibody was carried out (Figure 2). No signal was
detected in healthy animals, but a clear specific band at
a molecular mass of approximately 25 kDa was visible
in blots of serum from cirrhotic rats. These results indi-
cate that a single molecular entity is detected with the
CO3-610 antibody, in contrast to other serum collagen
ELISA assays reported previously, in which several frag-
ments of collagen were measured simultaneously [15].
Serum CO3-610 values rose in parallel with liver fibrosis
No difference was found between serum levels of CO3-
610 between control rats and those with mild/moderate
fibrosis (26.6 ± 1.3 ng/ml versus 28.5 ± 1.6 ng/ml,
respectively) (Figure 3A). However, progression of liver
fibrosis was associated with a parallel increase in the cir-
culating levels of the collagen III-derived epitope; values
significantly increased in rats with severe fibrosis (43.5 ±
3.3 ng/ml, P < 0.001) and reached maximum levels in
rats with cirrhosis (60.6 ± 4.3 ng/ml, P < 00.01). There
was a close direct relationship between CO3-610 values
and hepatic collagen content in CCl4-treated rats (r =
0.78; P < 0.001) (Figure 3B). These differences were
clearly greater than those obtained by calculating the
correlation coefficient between serum hyaluronic acid
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Figure 1 Classification of the study animals based on liver-collagen content. Photomicrographs of liver sections stained with Sirius red are
representative of control and treatment groups. Rats under CCl4 inhalation treatment were classified based on the evidence into three different
groups according to the histological quantification of their liver-collagen content: mild/moderate fibrosis (< 6% fibrotic area), severe fibrosis( 6t o
11% fibrotic area) and cirrhosis (> 11% fibrotic area). Original magnification ×100.
Table 1 Body weight, liver-function test results and serum electrolyte values in the rats of the study
Control (n = 20) Fibrosis
Mild/moderate (n = 33) Severe (n = 15) Cirrhosis (n = 20)
Body weight, g 399 ± 8 369 ± 6 367 ± 9 383 ± 9
ALT, U/L a 12.8 ± 1 88.6 ± 31.8 138.1 ± 71* 119.6 ± 31.5***
AST, U/L b 117 ± 23 219 ± 27 355 ± 92** 512 ± 69***
LDH, U/L c 1093 ± 106 1455 ± 154* 1386 ± 134* 917 ± 112
Albumin, g/l 36.1 ± 0.5 34.9 ± 0.5 33.3 ± 1.0 29.0 ± 0.8***
Serum Na
+, mEq/l 142 ± 1.6 142.6 ± 0.5 142.9 ± 0.4 141.5 ± 0.5*
Serum K
+, mEq/l 5.7 ± 0.2 6.0 ± 0.1 5.7 ± 0.1 4.8 ± 0.2
Serum osmolality, mOsm/Kg 292 ± 6 294 ± 3 291 ± 3 289 ± 1
a Alanine aminotransferase.
bAspartate aminotransferase.
cLactate dehydrogenase.
*P < 0.05; **P < 0.01 and ***P < 0.001 compared with control rats (one-way ANOVA with Newman-Keuls post hoc test and Kruskal–Wallis test with Dunn post hoc
tests as appropriate).
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and the hepatic collagen content in fibrotic/cirrhotic
rats (r = 0.49; P < 0.05).
Serum CO3-610 values closely correlate with portal
hypertension
Further insight into the suitability of CO-610 as a surro-
gate indicator of hepatic fibrosis was gained by measur-
ing mean arterial pressure (MAP) and portal pressure
(PP) in 20 of the 68 CCl4-treated rats included in the
protocol. This subset of animals did not differ from the
whole group of fibrotic/cirrhotic rats in terms of fibrosis
staging (seven rats with mild/moderate fibrosis, three
rats with severe fibrosis and ten rats with cirrhosis),
range of CO3-610 values (37.3 ± 5.6 ng/ml, 55.1 ± 6.3
ng/ml and 72.2 ± 6 ng/ml, respectively) or correlation
coefficient with hepatic collagen content (r = 0.71; P <
0.001). As previously observed, the increased disruption
in the hepatic architecture was associated with a pro-
gressive deterioration in systemic hemodynamics. In
fact, animals with cirrhosis had frank hypotension (MAP
96.5 ± 2.4 mmHg; P < 0.001) compared with control
rats (MAP 124.6 ± 2.4 mmHg). Accordingly MAP inver-
sely correlated with serum CO3-610 values in CCl4-trea-
ted rats (r =- 0 . 5 9 ;P < 0.01) (Figure 4A). However, the
most interesting finding of this investigation was that
the serum concentration of CO3-610 depicted a higher
direct relationship with the degree of portal hyperten-
sion in fibrotic/cirrhotic animals (r = 0.84; P <0 . 0 0 1 )
(Figure 4B).
Collagen types I and III are overexpressed in the hepatic
tissue of CCl4-treated rats
As expected, the expression of collagen 1a2( C o l 1 a2)
and 3a1( C o l 3 a1) mRNA was generally enhanced in
fibrotic/cirrhotic rats, but the pattern and degree of
changes clearly differed between the two transcripts
(Figure 5A). Collagen 1a2 mRNA expression increased
in parallel with the worsening of the liver disease. In cir-
rhotic rats this enhancement was around 20 times
higher than that in controls. This increase in the expres-
sion of collagen 3a1 mRNA reached its peak in the ani-
mals with fibrosis, and there was no worsening of this
level in the liver of rats with cirrhosis. Because CO3-610
is a degradation product of collagen type III, we next
examined the hepatic content of collagen type III in the
liver of CCl4-treated rats. Gene activation of collagen
3a1 mRNA was associated with a progressive deposition
of collagen III fibers in the hepatic tissue of animals
with induced fibrosis/cirrhosis protocol (Figure 5B),
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Figure 2 Immunoprecipitation of CO3-610 type III collagen
fragment from rat serum. CO3-610 was precipitated with
monoclonal antibodies from serum of a cirrhotic (F) rat treated with
CCl4 for 19 weeks and an untreated age-matched control (C) rat
and detected by western blotting as a single discrete protein band
of 25 kDa. The numbers on the right are the molecular masses of
Full-Range Rainbow Markers (Mr 12,000 to 225,000) from GE
Healthcare (Little Chalfont, United Kingdom). The figure is
representative of three independent experiments.
AB
r= 0.78
p<0.001
p<0.001
p<0.001
Figure 3 CO3-610 serum levels in experimental fibrosis
induced by chronic administration of carbon tetrachloride in
rats. (A) Serum concentrations of CO3-610 in control (untreated)
rats (n = 20), and rates with mild/moderate fibrosis (n = 33), severe
fibrosis (n = 15) and cirrhotic (n = 20). The box contains the values
between the 25th and 75th percentiles, and the horizontal line is
the median. Whiskers show the range of the data. Significance is
denoted versus the control animals. (B) Correlation of CO3-610
serum levels with histological quantification of liver fibrosis in all
CCl4-treated rats.
p< 0.001
r= 0.84
p< 0.01
r= -0.59
AB
Figure 4 Correlation of CO3-610 serum levels with portal
pressure (PP) and mean arterial pressure (MAP) in a group of
20 CCl4-treated rats.
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Page 4 of 10Figure 5 Hepatic expression of predominant collagen types and turnover regulators of extracellular matrix (ECM) in the study rats.
Animals were grouped as control, fibrosis and cirrhosis. Rats with mild, moderate and severe fibrosis were analyzed together as the fibrosis
group. (A) Collagens I and III transcription levels quantified by real-time PCR. (B) Immunolocalization of collagen type III in liver tissue. (C)
Hepatic gene expression of matrix metalloproteinase (Mmp)-2 and Mmp9, and tissue inhibitor of matrix metalloproteinase (Timp)-1 and Timp2
by real-time PCR. Data are expressed as mean ± SEM of the group, and P≤0.05 was considered significant (on top of the columns). Significance
is denoted versus the control group.
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of CCl4-treated rats
Following hepatic injury, increased matrix deposition of
collagen fibers results from an altered balance between
the activity of cleavage proteases such as MMPs and
their endogenous inhibitors, the TIMPs. Therefore, we
sought to determine expression of the rat genes Mmp2,
Mmp9, Timp1 and Timp2 in the liver of CCl4-treated
rats with different degrees of cirrhosis (Figure 5C).
Reverse transcriptase PCR analysis revealed marked
Mmp2 and Mmp9 mRNA overexpression in fibrotic rats
compared with control animals. A similar degree of
Mmp2 mRNA expression was apparent in cirrhotic rats;
however, the abundance of the Mmp9 transcript was
clearly attenuated in this group of animals. Timp1 and
-2 mRNAs were also significantly overexpressed in the
liver of CCl4-treated rats, with the higher intensity being
found in cirrhotic animals.
Discussion
It has recently been reported that human MMP-9 can
perform the initial cleavage of native collagens I and III,
with a clear substrate preference for type III over type I
[16]. A number of specific sequences of type III collagen
generated by MMP-9 have been identified previously
[17]. One of these, the neoepitope CO3-610, is also pro-
duced in rodents [13]. We previously reported that
CO3-610 levels are significantly increased in response to
BDL in Sprague-Dawley rats [14]. Rats had serum levels
2.3 times higher than those of matched sham controls at
2 and 4 weeks after surgery. Similarly, when we investi-
gated how CO3-610 responds to CCl4 intraperitoneal
injection, we found that serum levels doubled after 4
weeks of treatment, and remained significantly higher
than those of controls until week 8 [18].
In the present study, we found that fibrosis induced by
CCl4 inhalation in Wistar rats also resulted in increased
expression of the 25 kDa CO3-610 circulating fragment
(Figure 2). The fragment could be quantified by serum
ELISA, and used to differentiate the stages of hepatic
fibrosis in this experimental group. In particular, the
study marker could discriminate advanced fibrosis from
cirrhosis, and both from mild/moderate fibrosis and
normal liver conditions (Figure 3A). This suggests that
C O 3 - 6 1 0m a yb eo fu s ei na d v a n c e dd i s e a s ed i a g n o s i s ,
in the prognosis of liver-related events (hepatic coma or
liver-related death), or as a marker of treatment efficacy
in patients with cirrhosis. In the diagnosis of advanced
fibrosis, CO3-610 seems to add little extra value to the
already existing serum and imaging markers; however,
as a marker of treatment efficacy, it merits further
research considering that currently the greatest limita-
tion in bringing new antifibrotic drugs to the clinic is
the lack of clinical trial end points [7]. In contrast to
our previous studies in models of acute liver disease
[14,18] in which CO3-610 levels quickly responded to
the treatment in the context of high associated mortal-
ity, this study allowed us to observe how CO3-610 levels
correlated with histological fibrosis along a wide range
of fibrosis values (Figure 3B), and how CO3-610 can
effectively discriminate stages of severe fibrosis and cir-
rhosis from mild/moderate or no fibrosis, and between
both advanced stages of disease (Figure 3A).
A key finding in this paper is the relationship between
serum CO3-610 and PP, which was the strongest of all
variables studied. The assessment of hemodynamic para-
meters, together with liver biopsy examination, is a very
important tool for staging and prognosis in liver disease.
Furthermore, a recent study in patients with hepatitis C
virus after liver transplantation determined that a hepa-
tic venous pressure gradient value of 6 mm Hg or
higher was accurate at identifying patients at risk of dis-
ease progression (area under the curve 0.96) [19]. To
our knowledge, HA is the only serum marker that has
been confirmed as an independent predictor of portal
hypertension in patients with liver disease [20]. In our
study, compared with HA measurements in serum,
t h e r ew a sas t r o n g e rr e l a t i o n s h i pb e t w e e nC O 3 - 6 1 0a n d
hepatic collagen content during fibrosis, This is impor-
tant because HA is an ECM component whose serum
levels are closely associated with matrix deposition, and
it is generally considered one of the best available liver
fibrosis biomarkers. HA has been thoroughly studied in
both preclinical and clinical settings, and continues to
be tested in human liver disease as part of algorithmic
models that include other serum markers and clinical
variables [8,21,22].
Interstitial collagens type I and III are the main com-
ponents of the scar matrix that replaces the basal mem-
brane of the subendothelial space of Disse and sinusoid
during liver fibrosis [23,24]. Type I collagen transcrip-
tion is considered a sensitive marker of active fibrogen-
esis, with increased levels seen at an early stage in the
process [25,26]. In the study group, Col1a2t r a n s c r i p -
tion behaved as a quantitative index of fibrosis progres-
sion, whereas type III collagen transcription was
activated in fibrosis, but remained at similar levels in
cirrhosis (Figure 5A). This differential profile is not
apparent when animals are grouped according to the
time course of CCl4 exposure [24]. Type III collagen
protein accumulation continued to increase in cirrhotic
tissue (Figure 5B), probably due to decreases in intersti-
tial collagen degradation in advanced disease. Changes
in the activities of MMPs are considered one of the
main factors contributing to excess collagen deposition
in liver fibrosis [27]. We found a general overexpression
of both gelatinases during fibrosis (Figure 5C), in agree-
ment with previous reports [28-30]. However, rat Mmp9
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mals, but returned to control values. Similar expression
profiles have been published in previous reports [31,32],
with Mmp9 increases being associated with early liver
injury and inflammatory reaction, but not with the stage
of fibrosis, and they disappeared in advanced fibrosis.
Instead, Mmp2 levels increased with tissue inflamma-
tion, and were sustained at later stages. It is thought
that the initial role of MMP-9 in liver fibrosis is the
degradation of the normal basolateral matrix, and that
subsequent decreases in ECM breakdown by MMP-9
lead to ECM accumulation and exacerbation of liver
fibrosis. CCl4 treatment also induced increases in rat
Timp1 and -2 expression (Figure 5C). Interestingly,
Timp2 increases were significant only in cirrhotic rats.
Taken together, these results suggest that rat liver
Mmp9 production and activity may reach their peak
during fibrosis, but not cirrhosis. However, relevant
Mmp9 activity also depends upon release of the latent
form of the enzyme from cellular stores, and is heavily
regulated by interactions with different tissue factors
[33].
Conclusions
The results presented in this paper indicate that the type
III collagen neoepitope CO3-610 closely correlates with
hepatic collagen content and portal pressure in rats with
fibrosis. Taking into account that the CO3-610 amino
acid sequence is identical in rodent and human type III
collagen, our findings suggest that this peptide could
ultimately be a useful non-invasive biomarker of fibrosis
in patients with liver disease.
Methods
The study was performed according to the criteria of
the investigation and ethics committee of the Hospital
Clinic, Barcelona, Spain.
Induction of cirrhosis in rats and experimental procedures
The study was performed on 68 male Wistar rats with
different degrees of fibrosis and 20 control Wistar rats
(Charles-River, Saint Aubin les Elseuf, France). Fibrosis
was induced by repetitive CCl4 inhalation [34]. The rats
were fed ad libitum with standard chow and given
water containing phenobarbital 0.3 g/L as drinking fluid.
Animals were exposed to a CCl4 vapor atmosphere
twice a week, starting with 0.5 minutes per exposure.
The duration of exposure was increased by 1 minute
after every three session until it reached 5 minutes,
which was used until the end of the investigation. To
examine the effects of variable degrees of hepatic fibro-
sis, the CCl4-treated rats were examined at weeks 8 (n =
13), 13 (n = 26), 16 (n = 13) and 19 (n = 16) after start-
ing the fibrosis-induction protocol. For the analysis of
results, all treated animals were grouped according to
thresholds of histological fibrosis (Figure 1). Control rats
were studied after similar periods of phenobarbital
administration alone.
When scheduled, animals were anesthetized and a
hemodynamic study was performed when indicated. A
subgroup of 20 rats was selected to perform these mea-
surements before termination to measure MAP and PP.
A blood sample was then obtained from all animals to
measure osmolality, electrolytes, standard parameters of
liver function, and serum concentrations of HA and
CO3-610. Thereafter, the animals were killed by iso-
fluorane overdose (Forane, Abbott Laboratories S.A.,
Madrid, Spain), and hepatic samples were obtained from
the middle liver lobe, which were immediately frozen in
liquid nitrogen until further analysis of mRNA expres-
sion, or fixed in 10% buffered formalin for further analy-
sis with hematoxylin and eosin stain, Sirius red stain
and immunohistochemistry.
Hemodynamic measurements
Rats were anesthetized with barbiturate 100 mg/kg
body weight (Inactin
®; Sigma-Aldrich Chemie Gmbh,
Steinherim, Germany) and a polyvinyl catheter (PE-50;
; Becton-Dickinson, Franklin Lakes, NJ, USA) was
implanted in the left femoral artery. The arterial cathe-
ter was connected to a very sensitive transducer (Hew-
lett Packard, Avondale, PA, USA) that was calibrated
before each study. Hemodynamic parameters were
allowed to equilibrate for 30 minutes, and MAP and
heart rate values were recorded for two periods of 30
minutes. Each value represented the average of two
measurements. A midline abdominal incision (20 mm)
was made, and a PE-50 catheter was placed in the por-
tal vein through an ileocolic vein. After verifying free
blood reflux, the catheter was fixed to the mesentery
with cyanoacrylate glue, and PP was measured. Ani-
mals were killed by isofluorane overdose, and tissue
specimens were collected.
Quantification of fibrosis
Liver sections 4 μm thick were stained in 0.1% Sirius red
F3B (Sigma-Aldrich, St. Louis, MO, USA) in saturated
picric acid (Sigma-Aldrich). The relative fibrotic area,
expressed as a percentage of total liver area, was
assessed by analyzing 36 fields of Sirius red-stained liver
sections per animal. Each field was acquired at 10×
magnification with a microscope ( E600; Nikon, Tokyo,
Japan) and digital camera (RT-Slider Spot; Diagnostic
Instruments, Sterling Heights, MI, USA). Results were
analyzed using imaging software (ImageJ, NIH). To eval-
uate the relative fibrosis area, the measured collagen
area was divided by the net field area and then multi-
plied by 100. Subtraction of the vascular luminal area
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[35].
CO3-610 immunoprecipitation from serum
Serum samples from rats treated with CCl4 for 19 weeks
and from non-treated animals were analyzed in parallel.
Briefly, 1.5 μg/well of biotinylated anti-CO3-610 antibody
w a su s e dt oc o a ts t r e p t a v i d i n9 6 - w e l lp l a t e s( T h e r m o
Scientific Pierce, Rockford, IL, USA). Serum samples
(125 μL) were diluted 1:1 in immunoprecipitation buffer,
added to the wells, and incubated for 1 hour at room
temperature. Antibody-antigen complexes were removed
from non-specific binding, and the antigen eluted from
the plates according to the manufacturer’si n s t r u c t i o n s .
For western blotting analysis, 1.4 μlo fD T T1m o l / lw a s
added to 35 μL of each eluted sample, and then heated
for 5 minutes at 95°C. The heated samples were loaded
onto 15% SDS gels, resolved, and transferred to nitrocel-
lulose membranes using 60 mA for 90 minutes. Mem-
branes were blocked overnight in 5% milk, and incubated
f o raf u r t h e r2 . 5h o u r sw i t hh o r s e r a d i s hp e r o x i d a s e -
labeled anti-CO3-610 antibody (diluted 1:100). After
three washes of 10 minutes each, membranes were incu-
bated for a further 1 hour with anti-mouse IgG HRP-
linked secondary antibody (diluted 1:5000) followed by
another three washes of 10 minutes each. Membranes
were then developed with autoradiography films (GE
Healthcare, Piscataway, NJ, USA) for 30 minutes.
CO3-610 quantification in serum
Details on the design and production of the monoclonal
antibody against CO3-610 and the development of the
serum CO3-610 ELISA assay have been previously pub-
lished [13]. In brief, 100 μl of 2.5 ng/mL C-term biotiny-
lated peptide NB51 (KNGETGPQGP) in PBS-Tris-borate-
EDTA were used to coat streptavidin plates for 30 minutes
at 20°C on a 300 rpm shaker, and then removed with
washing buffer. Serum samples (20 μl) were diluted eight-
fold in incubation buffer (10 mmol/l: 400 mmol/l Tris:Bis-
Tris buffer) and added to the plates. Next, 100 μLo fC O 3 -
610 peroxidase conjugated antibody solution (1:40,000
dilution) was added to the plates and left to incubate over-
night at 4°C, on a 300 rpm shaker. The next day, plates
were washed five times in washing buffer, then 100 μlo f
3,3’,5,5’-tetramethylbenzidine was added, and the plates
incubated in darkness for 15 minutes at 20°C on a 300
rpm shaker. The reaction was stopped with the addition of
100 μL of stop solution, and plates were read on an ELISA
reader at 450 nm, with 650 nm as reference.
Messenger RNA expression of Col1a2, Col3a1, Mmp2,
Mmp9, Timp1 and TIMP2
Total RNA was extracted from frozen liver specimens of
control and fibrotic rats (RNeasy Kit; Qiagen, Hilden,
Germany), then 1 μg of total RNA was reverse tran-
scribed using a complementary DNA synthesis kit
(High-Capacity cDNA Reverse Transcription Kit;
Applied Biosystems, Foster City, CA, USA). RNA con-
centration was determined by spectrophotometric analy-
sis (ND-100 Spectrophotometer, Nanodrop
Technologies Inc., Wilmington, DE, USA). Total RNA
(1 μg) was reverse transcribed using the same comple-
mentary DNA synthesis kit described above. Specific
primers and probes used for the different genes studied
were designed to include intron spanning, using the
Universal Probe Library Assay Design Center through
the ProbeFinder software (version 2.45; Roche Diagnos-
tics, Indianapolis, IN, USA; https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp). The primers used
a r es h o w ni nT a b l e2 .P r i m e r sf o rr a tw e r ed e s i g n e d
according to GenBank sequences (NM_053356.1,
NM_032085.1, NM_053819.1, NM_021989.2,
NM_031054.2, NM_031055.1 and NM_012583.2, respec-
tively) and probes were designed using ProbeFinder soft-
ware as above.
Real-time quantitative PCR reactions were performed
in duplicate and analyzed (Light Cycler 480; Roche
Diagnostics). The PCR reaction mix was 10 μlt o t a l
volume, comprising 1:8 cDNA dilution, 200 nmol/l pri-
mer dilution, 100 nmol/l pre-validated nine-mer probe
(Universal ProbeLibrary, Roche Diagnostics) and a mas-
ter kit (FastStart Taqman Probe Master Kit; Roche Diag-
nostics). The hypoxanthine phosphoribosyltransferase 1
gene (Hprt1) was used as a reference gene for normali-
zation (Table 2), and water was used as negative control.
Relative quantification was calculated using the com-
parative threshold (CT) cycle, which is inversely related
to the abundance of mRNA transcripts in the initial
sample. The mean of CT duplicate measurements was
used to calculate ΔCT as the difference in CT for target
Table 2 Primers used for PCR
Primer name Sequence 5’®3’
Col1a2 Left AGACCTGGCGAGAGAGGAGT
Right ATCCAGACCGTTGTGTCCTC
Col3a1 Left TCCCCTGGAATCTGTGAATC
Right TGAGTCGAATTGGGGAGAAT
Timp1 Left CATGGAGAGCCTCTGTGGAT
Right TGTGCAAATTTCCGTTCCTT
Timp2 Left GACAAGGACATCGAATTTATCTACAC
Right CCATCTCCTTCCGCCTTC
Mmp2 Left GCGCTTTTCTCGAATCCAT
Right GGGTATCCATCTCCATGCTC
Mmp9 Left CCTGAAAACCTCCAACCTCA
Right GAGTGTAACCATAGCGGTACAGG
Hprt1 Left GACCGGTTCTGTCATGTCG
Right ACCTGGTTCATCATCACTAATCAC
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expressed as fold-induction of the target gene compared
with the reference gene according to the formula 2
-
ΔΔCT,w h e r eΔΔCT represents ΔCT values normalized
with the mean ΔCT of control samples.
Type III collagen immunohistochemical analysis
Sections of frozen liver tissue 5 μmt h i c kw e r ec u ta n d
fixed in acetone for 10 minutes, then dried overnight at
room temperature. Slides were washed in water for 5
minutes. Anti-type III collagen ab7778 primary antibody
(Abcam, Cambridge, UK) was diluted 1:50 with 1%
bovine albumin, and incubated on the slides for 30 min-
utes at room temperature, then removed with 0.1% Tri-
ton X-100 in PBS (two washes of 5 minutes each).
Slides were then incubated with secondary horseradish
peroxidase Envision anti-rabbit IgG antibody (Dako,
Glostrup, Denmark) for 30 minutes, and washed with
0 . 1 %T r i t o nX - 1 0 0( 2×5m i n u t e s ) .R e ds t a i n i n gw a s
produced by incubation with 3-amino-9-ethyl carbazole
substrate (Vector Laboratories, Burlingame, CA, USA)
for 30 minutes. Slides were counterstained with Meyers
hematoxylin.
Other measurements and statistical analysis
Serum levels of HA were quantified with an enzyme-
linked binding-protein assay according to the manufac-
turer’s instructions (Corgenix Inc, Westminster, CO,
USA). Serum osmolality was determined from osmo-
metric depression of the freezing point (Osmometer
3300; Advanced Instruments, Needham Heights, MA,
USA) and Na
+ and K
+ concentrations by flame photo-
metry (IL 943; Instrumentation Laboratory, Lexington,
MA, USA). Serum albumin, alanine transaminase and
lactate dehydrogenase were measured by a chemical
analyzer (ADVIA 2400; Siemens Healthcare Diagnostics,
T a r r y t o w n ,N Y ,U S A ) .Q u a n t i t a t i v ed a t aw e r ea n a l y z e d
using GraphPad Prism 5 (GraphPad Software, Inc., San
Diego, CA, USA). Differences between mean values
obtained from CCl4-treated and control groups were
analyzed using one-way ANOVA with Newman-Keuls
post hoc test, and Kruskal–Wallis test with Dunn post
hoc tests when appropriate. Correlations between serum
CO3-610 values and the rest of the variables studied
were analyzed with the Pearson two-tailed test. Data
was expressed as mean ± SEM, and P≤0.05 was consid-
ered significant.
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